β-Cyclodextrin dimers as potential tumor pretargeting agentsElectronic supplementary information (ESI) available: experimental section. See http://www.rsc.org/suppdata/cc/b1/b102814f/Abbreviations: Mabs, monoclonal antibodies; HILIC, hydrophilic interaction chromatography; HMQC, heteronuclear multiple quantam coherence; COSY, H–H correlated spectroscopy; MALDI-MS, matrix assisted laser desorption-ionization mass spectrometry; Kf, formation constant; BBC, 1,7-(4-tert-butylphenylmethyl)cyclen; Cu–BBC, copper-1,7-(4-tert-butylphenylmethyl)cyclen; ES-MS, electrospray mass spectrometry; HPLC, high pressure liquid chromatography; BNS, 6-(4-tert-butylphenylamino)naphthalene-2-sulfonic acid; KD, equilibrium dissociation constant; Ki, the concentration of the competing ligand that will bind to half the binding sites at equilibrium; IC50, concentration of competitive ligand that inhibits half of the binding of a ligand; Cheng–Prusoff equation, Ki = IC50(1 + [ligand]/KD,ligand)−1

Abstract

A β-cyclodextrin dimer binds a di-tert-butylbenzyl–Cu–cyclen with high affinity, demonstrating potential as a receptor/ligand system for tumor pretargeting with monoclonal antibodies.